Steven P Balk
Overview
Explore the profile of Steven P Balk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
172
Citations
8659
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Arai S, Gao Y, Yu Z, Xie L, Wang L, Zhang T, et al.
Commun Biol
. 2024 Jan;
7(1):25.
PMID: 38182874
Degradation of unliganded androgen receptor (AR) in prostate cancer cells can be prevented by proteasome inhibition, but this is associated with only modest increases in polyubiquitylated AR. An inhibitor (VLX1570)...
12.
Besschetnova A, Han W, Liu M, Gao Y, Li M, Wang Z, et al.
Cancer Res Commun
. 2023 Sep;
3(8):1716-1730.
PMID: 37663929
Significance: In this study, we demonstrate that EHMT1 and EHMT2 proteins drive prostate cancer development by transcriptionally activating multiple oncogenic pathways. Mechanistically, the chromatin binding of EHMT1 is significantly expanded...
13.
Iyer H, Vaselkiv J, Stopsack K, Roscoe C, DeVille N, Zhang Y, et al.
Am J Epidemiol
. 2023 May;
192(9):1485-1498.
PMID: 37139568
Adverse neighborhood social and natural (green space) environments may contribute to the etiology of prostate cancer (CaP), but mechanisms are unclear. We examined associations between neighborhood environment and prostate intratumoral...
14.
Li M, Liu M, Han W, Wang Z, Han D, Patalano S, et al.
Cancer Res
. 2023 Mar;
83(10):1684-1698.
PMID: 36877164
Significance: LSD1 drives prostate cancer progression by activating super-enhancer-mediated oncogenic programs, which can be targeted with the combination of LSD1 and BRD4 inhibitors to suppress the growth of CRPC.
15.
Wang K, Ma F, Arai S, Wang Y, Varkaris A, Poluben L, et al.
Cancer Res
. 2023 Jan;
83(7):1016-1030.
PMID: 36622276
Significance: WNT5a signaling through ROR2 activates the Hippo pathway to downregulate YAP1/TAZ activity and suppress tumor growth, identifying ROR2 as a potential biomarker to identify patients that could benefit from...
16.
Patterson J, Varkaris A, Croucher P, Ridinger M, Dalrymple S, Nouri M, et al.
Cancer Res
. 2022 Nov;
83(2):219-238.
PMID: 36413141
Significance: Abiraterone treatment induces mitotic defects that sensitize cancer cells to Plk1 inhibition, revealing an AR-independent mechanism for this synergistic combination that is applicable to a variety of cancer types.
17.
Sowalsky A, Figueiredo I, Lis R, Coleman I, Gurel B, Bogdan D, et al.
Clin Cancer Res
. 2022 Jun;
28(16):3509-3525.
PMID: 35695870
Purpose: Therapies targeting the androgen receptor (AR) have improved the outcome for patients with castration-sensitive prostate cancer (CSPC). Expression of the constitutively active AR splice variant-7 (AR-V7) has shown clinical...
18.
Varghese B, Lynch L, Vriend L, Draganov D, Clark J, Kissick H, et al.
Cancer Immunol Immunother
. 2022 May;
71(12):2943-2955.
PMID: 35523889
Invariant natural killer T cells (iNKT cells) express a semi-invariant T cell receptor that recognizes certain glycolipids (including α-galactosylceramide, αGC) bound to CD1d, and can induce potent antitumor responses. Here,...
19.
Mendes A, Lu J, Kaur H, Zheng S, Xu J, Hicks J, et al.
Cancer
. 2022 Mar;
128(12):2269-2280.
PMID: 35333400
Background: B7 homolog 3 (B7-H3) is an immunomodulatory molecule that is highly expressed in prostate cancer (PCa) and belongs to the B7 superfamily, which includes PD-L1. Immunotherapies (antibodies, antibody-drug conjugates,...
20.
Sentana-Lledo D, Sartor O, Balk S, Einstein D
Prostate
. 2022 Mar;
82(8):883-893.
PMID: 35254710
Background: Men of African ancestry (AA) with prostate cancer suffer from worse outcomes. However, a recent analysis of patients treated with the dendritic cell vaccine sipuleucel-T for prostate cancer suggested...